Harold C. Simmons Comprehensive Cancer Center
- World rank, all time
- #15,696 of 42,892
- Rank in ??
- #207 of 1,041
- Research works
- 221 ▲ 87% vs 2013–17
- Citations
- 11k 47.9 per fractional work
- Top-10% rate
- 25.6% record average 16.5%
- Open access
- 44% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 3.7×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 3.7×
- Medicine 3.4×
- Immunology and Microbiology 2.4×
- Economics, Econometrics and Finance 2.0×
- Health Professions 1.1×
- Dentistry 0.8×
- Mathematics 0.4×
- Chemistry 0.3×
- Nursing 0.2×
- Physics and Astronomy 0.2×
- Social Sciences 0.2×
- Decision Sciences 0.1×
- Environmental Science 0.1×
- Materials Science 0.1×
- Computer Science 0.0×
- Psychology 0.0×
- Engineering 0.0×
Who are the top researchers at Harold C. Simmons Comprehensive Cancer Center?
Ranked on the composite score, James K. V. Willson lead among researchers whose main affiliation is Harold C. Simmons Comprehensive Cancer Center.
- 1 James K. V. Willson ?? · #28,828 worldwide 654 citations · 39 works
Which keywords describe research at Harold C. Simmons Comprehensive Cancer Center?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Immunotherapy, Chemotherapy, Prognostic Factors, Cancer, Targeted Therapy, Lymphoma, Breast Cancer and Clinical Trials.
- Nephron-Sparing Surgery
- CDK4/6 Inhibitors
- Radiotherapy
- Classification
- Neoadjuvant Therapy
- Immune Checkpoint Blockade
- CAR T Cells
- Metastatic
- Metastasis
- Gene Expression Profiling
- Cancer Immunotherapy
- Mutational Signatures
- Clinical Practice Guidelines
- Therapy
- Genetic Mutations
- Molecular Characterization
- Clinical Trials
- Lymphoma
- Cancer
- Chemotherapy
- Immunotherapy
- Prognostic Factors
- Targeted Therapy
- Breast Cancer
- Tumor Microenvironment
- Rituximab
- PET Imaging
- Cancer Genomics
- Molecular Profiling
- Tumor Regression
- Clinical Guidelines
- Leukemia
- Cancer Incidence
- Biomarkers
- Chimeric Antigen Receptor
- Metastatic Breast Cancer
- PD-1 and PD-L1
- Genetic Pathogenesis
- Signaling
- Palbociclib
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Immunotherapy5▲ 17×16 topics
- Chemotherapy4▲ 15×21 topics
- Prognostic Factors4▲ 21×12 topics
- Cancer4▲ 6.3×22 topics
- Targeted Therapy3▲ 34×4 topics
- Lymphoma3▲ 41×3 topics
- Breast Cancer2▲ 26×7 topics
- Clinical Trials2▲ 9.0×7 topics
- Tumor Microenvironment2▲ 14×7 topics
- Molecular Characterization2▲ 26×4 topics
- Rituximab2▲ 28×2 topics
- Genetic Mutations2▲ 9.6×9 topics
- PET Imaging2▲ 24×4 topics
- Therapy2▲ 20×4 topics
- Cancer Genomics2▲ 53×1 topic
- Clinical Practice Guidelines2▲ 6.9×8 topics
- Molecular Profiling2▲ 38×3 topics
- Mutational Signatures2▲ 53×1 topic
- Tumor Regression2▲ 37×2 topics
- Cancer Immunotherapy2▲ 23×3 topics
- Clinical Guidelines2▲ 12×5 topics
- Gene Expression Profiling2▲ 44×2 topics
- Leukemia2▲ 43×2 topics
- Metastasis2▲ 10×9 topics
- Cancer Incidence1▲ 25×4 topics
- Metastatic1▲ 55×2 topics
- Biomarkers1▲ 4.6×5 topics
- CAR T Cells1▲ 43×1 topic
- Chimeric Antigen Receptor1▲ 43×1 topic
- Immune Checkpoint Blockade1▲ 28×1 topic
- Metastatic Breast Cancer1▲ 55×2 topics
- Neoadjuvant Therapy1▲ 13×5 topics
- PD-1 and PD-L11▲ 28×1 topic
- Classification1▲ 6.5×1 topic
- Genetic Pathogenesis1▲ 55×1 topic
- Radiotherapy1▲ 7.4×8 topics
- Signaling1▲ 50×3 topics
- CDK4/6 Inhibitors1▲ 111×1 topic
- Palbociclib1▲ 111×1 topic
- Nephron-Sparing Surgery1▲ 73×1 topic
Which research topics does Harold C. Simmons Comprehensive Cancer Center publish most on?
By volume in 2022–2025: Cancer Genomics and Diagnostics, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers and Lymphoma Diagnosis and Treatment.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Genomics and Diagnostics Cancer Research 2 works
- 2 CAR-T cell therapy research Oncology 1 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 4 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 1 works
- 5 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 6 Renal cell carcinoma treatment Pulmonary and Respiratory Medicine 1 works
- 7 Economic and Financial Impacts of Cancer Economics and Econometrics 1 works
- 8 Renal and related cancers Molecular Biology 1 works
- 9 Lung Cancer Research Studies Oncology 1 works
- 10 Palliative Care and End-of-Life Issues Public Health, Environmental and Occupational Health 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Harold C. Simmons Comprehensive Cancer Center's research output changed?
Output in 2018–2022 was 87% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Dallas
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.